Skip to main content
SpringerLink
Log in

Atherosclerosis, Hypertension and Aging

  • Chapter
Aging and the Heart

  • 754 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lundberg MS, Crow MT. Age-related changes in the signaling and function of vascular smooth muscle cells. Exp Gerontol 1999;34:549–557

    Article  PubMed  CAS  Google Scholar 

  2. Bilato C, Crow MT. Atherosclerosis and the vascular biology of aging. Aging (Milano) 1996;8:221–234

    CAS  Google Scholar 

  3. Pauly RR, Bilato C, Sollott SJ, Monticone R, Kelly PT, Lakatta EG, Crow MT. Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation 1995;91:1107–1115

    PubMed  CAS  Google Scholar 

  4. Lusis AJ. Atherosclerosis. Nature 2000;407:233–241

    Article  PubMed  CAS  Google Scholar 

  5. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003;111:1795–1803

    Article  PubMed  CAS  Google Scholar 

  6. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987;76:504–507

    PubMed  CAS  Google Scholar 

  7. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989;86:587–591

    Article  PubMed  CAS  Google Scholar 

  8. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154–156

    Article  PubMed  CAS  Google Scholar 

  9. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2003;23:1963–1970

    Article  PubMed  CAS  Google Scholar 

  10. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001;292:1394–1398

    Article  PubMed  CAS  Google Scholar 

  11. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen A, Rivera CR, Mulvihill SJ, Malloy MJ, Kane JP. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002;110:109–117

    Article  PubMed  CAS  Google Scholar 

  12. McGill HC Jr, McMahan CA, Kruski AW, Mott GE. Relationship of lipoprotein cholesterol concentrations to experimental atherosclerosis in baboons. Arteriosclerosis 1981;1:3–12

    Google Scholar 

  13. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:85–91

    PubMed  CAS  Google Scholar 

  14. Hoff HF, Bradley WA, Heideman CL, Gaubatz JW, Karagas MD, Gotto AM Jr. Characterization of low density lipoprotein-like particle in the human aorta from grossly normal and atherosclerotic regions. Biochim Biophys Acta 1979;573:361–374

    PubMed  CAS  Google Scholar 

  15. Grundy SM. Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem 1995;41:139–146

    PubMed  CAS  Google Scholar 

  16. Joossens JV. Mechanisms of hypercholesterolemia and atherosclerosis. Acta Cardiol Suppl 1988;29:63–83

    PubMed  CAS  Google Scholar 

  17. Kesaniemi YA, Grundy SM. Increased low density lipoprotein production associated with obesity. Arteriosclerosis 1983;3:170–177

    PubMed  CAS  Google Scholar 

  18. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991;87:591–596

    PubMed  CAS  Google Scholar 

  19. Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med 1987;82:54–60

    Article  PubMed  CAS  Google Scholar 

  20. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336–345

    Google Scholar 

  21. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999;22: 347–351

    Article  PubMed  CAS  Google Scholar 

  22. Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasek-McKenna D, O’Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH Jr, Gu JZ. Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds. J Lipid Res 2000;41:433–441

    PubMed  CAS  Google Scholar 

  23. Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, Peterson KM, Koch C, Arnould I, Prades C, Duverger N, Funke H, Assman G, Dinger M, Dean M, Chimini G, Santamarina-Fojo S, Fredrickson DS, Denefle P, Brewer HB Jr. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA 1999;96:12685–12690

    Article  PubMed  CAS  Google Scholar 

  24. Klein HG, Santamarina-Fojo S, Duverger N, Clerc M, Dumon MF, Albers JJ, Marcovina S, Brewer HB Jr. Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. J Clin Invest 1993;92:479–485

    Article  PubMed  CAS  Google Scholar 

  25. Kuivenhoven JA, Stalenhoef AF, Hill JS, Demacker PN, Errami A, Kastelein JJ, Pritchard PH. Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler Thromb Vasc Biol 1996;16: 294–303

    Google Scholar 

  26. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004;109: III8–III14

    Article  PubMed  CAS  Google Scholar 

  27. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003;14:347–352

    Article  PubMed  CAS  Google Scholar 

  28. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994;49:M252–M257

    PubMed  CAS  Google Scholar 

  29. Traissac T, Salzmann M, Rainfray M, Emeriau JP, Bourdel-Marchasson I. [Significance of cholesterol levels in patients 75 years or older]. Presse Med. 2005;34:1525–1532

    PubMed  CAS  Google Scholar 

  30. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003;163:1549–1554

    Article  PubMed  CAS  Google Scholar 

  31. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290:2030–2040

    Article  PubMed  CAS  Google Scholar 

  32. Barbagallo CM, Averna MR, Frada G, Noto D, Cavera G, Notarbartolo A. Lipoprotein profile and high-density lipoproteins: subfractions distribution in centenarians. Gerontology 1998;44:106–110

    Article  PubMed  CAS  Google Scholar 

  33. Arai Y, Hirose N, Nakazawa S, Yamamura K, Shimizu K, Takayama M, Ebihara Y, Osono Y, Homma S. Lipoprotein metabolism in Japanese centenarians: effects of apolipoprotein E polymorphism and nutritional status. J Am Geriatr Soc 2001;49:1434–1441

    Article  PubMed  CAS  Google Scholar 

  34. Middelberg RP, Spector TD, Swaminathan R, Snieder H. Genetic and environmental influences on lipids, lipoproteins, and apolipoproteins: effects of menopause. Arterioscler Thromb Vasc Biol 2002;22:1142–1147

    Article  PubMed  CAS  Google Scholar 

  35. Middelberg RP, Martin NG, Whitfield JB. Longitudinal genetic analysis of plasma lipids. Twin Res Hum Genet 2006;9:550–557

    Article  PubMed  Google Scholar 

  36. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234–1238

    Article  PubMed  CAS  Google Scholar 

  37. Yamashita S, Hui DY, Wetterau JR, Sprecher DL, Harmony JA, Sakai N, Matsuzawa Y, Tarui S. Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. Metabolism 1991;40:756–763

    Article  PubMed  CAS  Google Scholar 

  38. Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, Arai T, Yanagi K, Takami S, Menju M, Ishigami M, Yoshida Y, Kameda-Takemura K, Hayashi K, Matsuzawa Y. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995;15:1849–1856

    PubMed  CAS  Google Scholar 

  39. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967–1974

    Article  PubMed  CAS  Google Scholar 

  40. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 2005;178:217–30

    Article  PubMed  CAS  Google Scholar 

  41. Arai Y, Hirose N, Yamamura K, Nakazawa S, Shimizu K, Takayama M, Ebihara Y, Homma S, Gondo Y, Masui Y, Inagaki H. Deficiency of choresteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity. J Mol Med 2003;81:102–109

    PubMed  CAS  Google Scholar 

  42. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998;39:1071–1078

    PubMed  CAS  Google Scholar 

  43. Gronholdt ML, Sillesen H, Wiebe BM, Laursen H, Nordestgaard BG. Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. Eur J Vasc Endovasc Surg 2001;21: 227–234

    Article  PubMed  CAS  Google Scholar 

  44. Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000;32:579–583

    Article  PubMed  CAS  Google Scholar 

  45. Arai Y, Hirose N. Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb 2004;11:246–252

    PubMed  CAS  Google Scholar 

  46. Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 2000;121:255–260

    Article  PubMed  CAS  Google Scholar 

  47. Ansell BJ, Watson KE, Weiss RE, Fonarow GC. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels a clinical investigation. Heart Dis 2003;5:2–7

    Article  PubMed  CAS  Google Scholar 

  48. Karaca I, Ilkay E, Akbulut M, Yavuzkir M, Pekdemir M, Akbulut H, Arslan N. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Curr Med Res Opin 2003;19:187–191

    Article  PubMed  CAS  Google Scholar 

  49. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191–1193

    PubMed  CAS  Google Scholar 

  50. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115–126

    Article  PubMed  CAS  Google Scholar 

  51. Mosinger BJ. Human low-density lipoproteins: oxidative modification and its relation to age, gender, menopausal status and cholesterol concentrations. Eur J Clin Chem Clin Biochem 1997;35:207–214

    PubMed  CAS  Google Scholar 

  52. Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, Simonsick EM, Colbert LH, Kritchevsky SB. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003;23:1444–1448

    Article  PubMed  CAS  Google Scholar 

  53. Nakamura YK, Read MH, Elias JW, Omaye ST. Oxidation of serum low-density lipoprotein (LDL) and antioxidant status in young and elderly humans. Arch Gerontol Geriatr 2006;42:265–276

    Article  PubMed  CAS  Google Scholar 

  54. Stulnig TM, Jurgens G, Chen Q, Moll D, Schonitzer D, Jarosch E, Wick G. Properties of low density lipoproteins relevant to oxidative modifications change paradoxically during aging. Atherosclerosis 1996;126:85–94

    Article  PubMed  CAS  Google Scholar 

  55. Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med 2001;11:139–142

    Article  PubMed  CAS  Google Scholar 

  56. Tokumura A, Sumida T, Toujima M, Kogure K, Fukuzawa K. Platelet-activating factor (PAF)-like oxidized phospholipids: relevance to atherosclerosis. Biofactors 2000;13:29–33

    PubMed  CAS  Google Scholar 

  57. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284–287

    Article  PubMed  CAS  Google Scholar 

  58. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002;106:484–490

    Article  PubMed  CAS  Google Scholar 

  59. Miyoshi M, Nakano Y, Sakaguchi T, Ogi H, Oda N, Suenari K, Kiyotani K, Ozono R, Oshima T, Yoshida T, Chayama K. Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet. Hypertens Res 2007;30:85–91

    Article  PubMed  CAS  Google Scholar 

  60. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346: 869–872

    Article  PubMed  CAS  Google Scholar 

  61. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:2257–2260

    Article  PubMed  CAS  Google Scholar 

  62. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36–44

    Article  PubMed  CAS  Google Scholar 

  63. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997;17:1067–1073

    PubMed  CAS  Google Scholar 

  64. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997;17:3565–3569

    PubMed  CAS  Google Scholar 

  65. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435–442

    Article  PubMed  CAS  Google Scholar 

  66. Aynacioglu AS, Kepekci Y. The human paraoxonase Gln-Argl92 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 2000;74:33–37

    Article  PubMed  CAS  Google Scholar 

  67. Gardemann A, Philipp M, Hes K, Katz N, Tillmanns H, Haberbosch W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421–431

    Article  PubMed  CAS  Google Scholar 

  68. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998;141:259–264

    Article  PubMed  CAS  Google Scholar 

  69. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998;18:1611–1616

    PubMed  CAS  Google Scholar 

  70. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI. WISE Study Group. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 2003;72:13–22

    Google Scholar 

  71. Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, Channer K, Cheng S, Lindpaintner K, Samani NJ. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 2004;25:459–467

    Article  PubMed  CAS  Google Scholar 

  72. Senti M, Tomas M, Vila J, Marrugat J, Elosua R, Sala J, Masia R. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Atherosclerosis 2001;156:443–449

    Article  PubMed  CAS  Google Scholar 

  73. Baum L, Ng HK, Woo KS, Tomlinson B, Rainer TH, Chen X, Cheung WS, Chan DK, Thomas GN, Tong CS, Wong KS. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006;39:191–195

    Article  PubMed  CAS  Google Scholar 

  74. Saeed M, Perwaiz Iqbal M, Yousuf FA, Perveen S, Shafiq M, Sajid J, Frossard PM. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin Genet 2007;71:238–244

    Article  PubMed  CAS  Google Scholar 

  75. Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, Friso S, Tenuti I, Cheng S, Grow MA, Pignatti PF, Corrocher R. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 2004;34:14–20

    Article  PubMed  CAS  Google Scholar 

  76. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development – clinical and animal studies. Clin Chim Acta 2004;348:1–8

    Article  PubMed  CAS  Google Scholar 

  77. Ramachandran A, Levonen AL, Brookes PS, Ceaser E, Shiva S, Barone MC, Darley-Usmar rley-Usmar V. Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic Biol Med 2002;33:1465–1474

    Article  PubMed  CAS  Google Scholar 

  78. Zmijewski JW, Moellering DR, Le GC, Landar A, Ramachandran A, Darley-Usmar VM. Oxidized LDL induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol 2005;289:H852–H861

    Google Scholar 

  79. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006;185:219–226

    Article  PubMed  CAS  Google Scholar 

  80. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002;95:89–100

    Article  PubMed  CAS  Google Scholar 

  81. Adachi H, Tsujimoto M. Endothelial scavenger receptors. Prog Lipid Res 2006;45:379–404

    Article  PubMed  CAS  Google Scholar 

  82. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131–138

    PubMed  CAS  Google Scholar 

  83. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254–257

    Article  PubMed  CAS  Google Scholar 

  84. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134–5138

    Article  PubMed  CAS  Google Scholar 

  85. Palkama T. Induction of interleukin-1 production by ligands binding to the scavenger receptor in human monocytes and the THP-1 cell line. Immunology 1991;74:432–438

    PubMed  CAS  Google Scholar 

  86. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219–4225

    PubMed  CAS  Google Scholar 

  87. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005;85:9–23

    Article  PubMed  CAS  Google Scholar 

  88. Auer J, Weber T, Berent R, Lassnig E, Lamm G, Eber B. Genetic polymorphisms in cytokine and adhesion molecule genes in coronary artery disease. Am J Pharmacogenomics 2003;3:317–328

    Article  PubMed  CAS  Google Scholar 

  89. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007 Mar 14

    Google Scholar 

  90. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003;23:15–44

    Article  PubMed  CAS  Google Scholar 

  91. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103–3108

    Article  PubMed  CAS  Google Scholar 

  92. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158–1161

    PubMed  CAS  Google Scholar 

  93. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, Takeuchi O, Akira S. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-alpha induction. J Exp Med 2005;201:15–923

    Article  CAS  Google Scholar 

  94. Ruckdeschel K, Pfaffinger G, Haase R, Sing A, Weighardt H, Hacker G, Holzmann B, Heesemann J. Signaling of apoptosis through TLRs critically involves toll/IL-1 receptor domain-containing adapter inducing IFN-beta, but not MyD88, in bacteria-infected murine macrophages. J Immunol 2004;173:3320–3328

    PubMed  CAS  Google Scholar 

  95. Blessing E, Campbell LA, Rosenfeld ME, Chough N, Kuo CC. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 2001;158:13–17

    Article  PubMed  CAS  Google Scholar 

  96. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001;103:2834–2838

    PubMed  CAS  Google Scholar 

  97. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158–1161

    PubMed  CAS  Google Scholar 

  98. Schwartz DA, Cook DN. Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 2005;41:S403–S407

    Article  PubMed  CAS  Google Scholar 

  99. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet 2000;25:187–191

    Article  PubMed  CAS  Google Scholar 

  100. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185–192

    Article  PubMed  CAS  Google Scholar 

  101. Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007;38:1179–1184

    Article  PubMed  Google Scholar 

  102. Hamann L, Glaeser C, Hamprecht A, Gross M, Gomma A, Schumann RR. Toll-like receptor (TLR)-9 promotor polymorphisms and atherosclerosis. Clin Chim Acta 2006;364:303–307

    Article  PubMed  CAS  Google Scholar 

  103. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, Maggi FM, Catapano AL. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med 2005;258:21–27

    Article  PubMed  CAS  Google Scholar 

  104. Hernesniemi J, Lehtimaki T, Rontu R, Islam MS, Eklund C, Mikkelsson J, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Hurme M, Karhunen PJ. Toll-like receptor 4 polymorphism is associated with coronary stenosis but not with the occurrence of acute or old myocardial infarctions. Scand J Clin Lab Invest. 2006;66:667–675

    Google Scholar 

  105. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, Lamotte M, Lebret D, Ollivier V, de Prost D. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23:e61–e64

    Article  PubMed  CAS  Google Scholar 

  106. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW. Regression growth evaluation statin study group. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003;107:2416–2421

    Google Scholar 

  107. Hamann L, Gomma A, Schroder NW, Stamme C, Glaeser C, Schulz S, Gross M, Anker SD, Fox K, Schumann RR. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med 2005;83:478–485

    Article  PubMed  CAS  Google Scholar 

  108. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 2004;20:455–480

    Article  PubMed  CAS  Google Scholar 

  109. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001;98:507–512

    Article  PubMed  CAS  Google Scholar 

  110. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161–171

    Article  PubMed  CAS  Google Scholar 

  111. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7: 53–58

    Article  PubMed  CAS  Google Scholar 

  112. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241–252

    Article  PubMed  CAS  Google Scholar 

  113. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998;93:229–240

    Article  PubMed  CAS  Google Scholar 

  114. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523–531

    PubMed  CAS  Google Scholar 

  115. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004;114:1564–1567

    Article  PubMed  CAS  Google Scholar 

  116. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9:213–219

    Article  PubMed  CAS  Google Scholar 

  117. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79–82

    Article  PubMed  CAS  Google Scholar 

  118. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759–763

    Article  PubMed  CAS  Google Scholar 

  119. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res 1999;41:323–333

    Article  PubMed  CAS  Google Scholar 

  120. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004;110:337–343

    Article  PubMed  CAS  Google Scholar 

  121. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004;17:35–44

    Article  PubMed  CAS  Google Scholar 

  122. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005;46:1209–1218

    Article  PubMed  CAS  Google Scholar 

  123. Jarvisalo MJ, Juonala M, Raitakari OT. Assessment of inflammatory markers and endothelial function. Curr Opin Clin Nutr Metab Care 2006;9:547–552

    PubMed  CAS  Google Scholar 

  124. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006;17:502–509

    Article  PubMed  CAS  Google Scholar 

  125. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin Chem 2006;52:1645–1650

    Article  PubMed  CAS  Google Scholar 

  126. Baird AE. Blood biologic markers of stroke: improved management, reduced cost? Curr Atheroscler Rep 2006;8:267–275

    Article  PubMed  CAS  Google Scholar 

  127. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:III27–III32

    PubMed  Google Scholar 

  128. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J 2003;17:1183–1185

    PubMed  CAS  Google Scholar 

  129. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol Genom 2004;17:21–30

    Article  CAS  Google Scholar 

  130. Tuomisto TT, Yla-Herttuala S. What have we learnt about microarray analyses of atherogenesis? Curr Opin Lipidol 2005;16:201–205

    Article  PubMed  CAS  Google Scholar 

  131. Tuomisto TT, Korkeela A, Rutanen J, Viita H, Brasen JH, Riekkinen MS, Rissanen TT, Karkola K, Kiraly Z, Kolble K, Yla-Herttuala S. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler Thromb Vasc Biol 2003;23:2235–2240

    Article  PubMed  CAS  Google Scholar 

  132. Satterthwaite G, Francis SE, Suvarna K, Blakemore S, Ward C, Wallace D, Braddock M, Crossman D. Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am Heart J 2005;150:488–499

    Article  PubMed  CAS  Google Scholar 

  133. Gagarin D, Yang Z, Butler J, Wimmer M, Du B, Cahan P, McCaffrey TA. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J Mol Cell Cardiol 2005;39:453–465

    Article  PubMed  CAS  Google Scholar 

  134. Randi AM, Biguzzi E, Falciani F, Merlini P, Blakemore S, Bramucci E, Lucreziotti S, Lennon M, Faioni EM, Ardissino D, Mannucci PM. Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis. J Thromb Haemost 2003;1:829–835

    Article  PubMed  CAS  Google Scholar 

  135. Csoka AB, English SB, Simkevich CP, Ginzinger DG, Butte AJ, Schatten GP, Rothman FG, Sedivy JM. Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell 2004;3:235–243

    Article  PubMed  CAS  Google Scholar 

  136. Bijnens AP, Lutgens E, Ayoubi T, Kuiper J, Horrevoets AJ, Daemen MJ. Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. Arterioscler Thromb Vasc Biol 2006;26:1226–1235

    Article  PubMed  CAS  Google Scholar 

  137. Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, Suckling KE, James CH, Greaves DR, Patel L. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006;26:1837–1844

    Article  PubMed  CAS  Google Scholar 

  138. Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, Dong C, Vata K, Milano CA, Rigat F, Pittman J, Nevins JR, West M, Goldschmidt-Clermont PJ. Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:1922–1927

    Article  PubMed  CAS  Google Scholar 

  139. King JY, Ferrara R, Tabibiazar R, Spin JM, Chen MM, Kuchinsky A, Vailaya A, Kincaid R, Tsalenko A, Deng DX, Connolly A, Zhang P, Yang E, Watt C, Yakhini Z, Ben-Dor A, Adler A, Bruhn L, Tsao P, Quertermous T, Ashley EA. Pathway analysis of coronary atherosclerosis. Physiol Genomics 2005;23:103–118

    Article  PubMed  CAS  Google Scholar 

  140. Deng DX, Tsalenko A, Vailaya A, Ben-Dor A, Kundu R, Estay I, Tabibiazar R, Kincaid R, Yakhini Z, Bruhn L, Quertermous T. Differences in vascular bed disease susceptibility reflect differences in gene expression response to atherogenic stimuli. Circ Res 2006;98:200–208

    Article  PubMed  CAS  Google Scholar 

  141. Beauchamp NJ, van Achterberg TA, Engelse MA, Pannekoek H, de Vries CJ. Gene expression profiling of resting and activated vascular smooth muscle cells by serial analysis of gene expression and clustering analysis. Genomics 2003;82:288–299

    Google Scholar 

  142. Zhang QJ, Goddard M, Shanahan C, Shapiro L, Bennett M. Differential gene expression in vascular smooth muscle cells in primary atherosclerosis and in stent stenosis in humans. Arterioscler Thromb Vasc Biol 2002;22:2030–2036

    Article  PubMed  CAS  Google Scholar 

  143. Jang WG, Kim HS, Park KG, Park YB, Yoon KH, Han SW, Hur SH, Park KS, Lee IK. Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid. Proteomics 2004;4:3383–3393

    Article  PubMed  CAS  Google Scholar 

  144. Martinet W, Schrijvers DM, De Meyer GR, Thielemans J, Knaapen MW, Herman AG, Kockx MM. Gene expression profiling of apoptosis-related genes in human atherosclerosis: upregulation of death-associated protein kinase. Arterioscler Thromb Vasc Biol 2002;22:2023–2029

    Article  PubMed  CAS  Google Scholar 

  145. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, Okura T, Higaki J, Graf K, Fleck E, Hsueh WA, Law RE. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004;110:579–587

    Article  PubMed  CAS  Google Scholar 

  146. McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, Deutsch E, Tarazona N, Shaknovitch A, Newman G, Patterson C, Bush HL Jr. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999;31:1627–1642

    Article  PubMed  CAS  Google Scholar 

  147. Bray PJ, Du B, Mejia VM, Hao SC, Deutsch E, Fu C, Wilson RC, Hanauske-Abel H, McCaffrey TA. Glucocorticoid resistance caused by reduced expression of the glucocorticoid receptor in cells from human vascular lesions. Arterioscler Thromb Vasc Biol 1999;19:1180–1189

    PubMed  CAS  Google Scholar 

  148. Gagarin D, Yang Z, Butler J, Wimmer M, Du B, Cahan P, McCaffrey TA. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J Mol Cell Cardiol 2005;39:453–465

    Article  PubMed  CAS  Google Scholar 

  149. Vazquez-Padron RI, Lasko D, Li S, Louis L, Pestana IA, Pang M, Liotta C, Fornoni A, Aitouche A, Pham SM. Aging exacerbates neointimal formation, and increases proliferation and reduces susceptibility to apoptosis of vascular smooth muscle cells in mice. J Vasc Surg 2004;40:1199–1207

    Article  PubMed  Google Scholar 

  150. Kang JG, Patino WD, Matoba S, Hwang PM. Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med 2006;16:163–168

    Article  PubMed  CAS  Google Scholar 

  151. Baba MI, Kaul D, Grover A. Importance of blood cellular genomic profile in coronary heart disease. J Biomed Sci 2006;13:17–26

    Article  PubMed  CAS  Google Scholar 

  152. Miller DT, Ridker PM, Libby P, Kwiatkowski DJ. Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 2007;49:1589–1599

    Article  PubMed  CAS  Google Scholar 

  153. Llaverias G, Noe V, Penuelas S, Vazquez-Carrera M, Sanchez RM, Laguna JC, Ciudad CJ, Alegret M. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 2004;318:265–274

    Article  PubMed  CAS  Google Scholar 

  154. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 2004;11:62–72

    PubMed  CAS  Google Scholar 

  155. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993–1007

    Article  PubMed  CAS  Google Scholar 

  156. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105:290–292

    Article  PubMed  CAS  Google Scholar 

  157. Nilsson J, Nordin Fredrikson G, Schiopu A, Shah PK, Jansson B, Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Curr Pharm Des 2007;13:1021–1030

    Article  PubMed  CAS  Google Scholar 

  158. Robinson I, de Serna DG, Gutierrez A, Schade DS. Vitamin E in humans: an explanation of clinical trial failure. Endocr Pract 2006;12:576–582

    PubMed  Google Scholar 

  159. Williams KJ, Fisher EA. Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory? Curr Opin Clin Nutr Metab Care 2005;8:139–146

    Article  PubMed  CAS  Google Scholar 

  160. Cherubini A, Vigna GB, Zuliani G, Ruggiero C, Senin U, Fellin R. Role of antioxidants in atherosclerosis: epidemiological and clinical update. Curr Pharm Des 2005;11:2017–2032

    Article  PubMed  CAS  Google Scholar 

  161. Li D, Mehta JL. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium 2003;10:17–21

    Article  PubMed  Google Scholar 

  162. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004;173:1–12

    Article  PubMed  CAS  Google Scholar 

  163. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007;28:664–672

    Article  PubMed  CAS  Google Scholar 

  164. Nachimuthu S, Raggi P. Novel agents to manage dyslipidemias and impact atherosclerosis. Cardiovasc Hematol Disord Drug Targets 2006;6:209–217

    PubMed  CAS  Google Scholar 

  165. Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 2006;26:706–715

    Article  PubMed  CAS  Google Scholar 

  166. Kraaijeveld AO, de Jager SC, van Berkel TJ, Biessen EA, Jukema JW. Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? Curr Pharm Des 2007;13:1039–1052

    Article  PubMed  CAS  Google Scholar 

  167. Reutershan J. CXCR2–the receptor to hit? Drug News Perspect 2006;19:615–623

    Article  PubMed  CAS  Google Scholar 

  168. Campbell IW. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005;5:349–363

    Article  PubMed  CAS  Google Scholar 

  169. Grabar P. Hypothesis. Auto-antibodies and immunological theories: an analytical review. Clin Immunol Immunopathol 1975;4:453–466

    Google Scholar 

  170. Witztum JL. Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? J Clin Invest 2002;109:721–724

    Article  PubMed  CAS  Google Scholar 

  171. Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the 1939–45 war. Lancet 1977;2:127–129

    PubMed  CAS  Google Scholar 

  172. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002;109:745–753

    Article  PubMed  CAS  Google Scholar 

  173. Weksler ME, Goodhardt M. Do age-associated changes in ’physiologic’ autoantibodies contribute to infection, atherosclerosis, and Alzheimer’s disease? Exp Gerontol 2002;37:971–979

    Article  PubMed  CAS  Google Scholar 

  174. Riley SC, Froscher BG, Linton PJ, Zharhary D, Marcu K, Klinman NR. Altered VH gene segment utilization in the response to phosphorylcholine by aged mice. J Immunol 1989;143:3798–3805

    PubMed  CAS  Google Scholar 

  175. Nicoletti C. Antibody protection in aging: influence of idiotypic repertoire and antibody binding activity to a bacterial antigen. Exp Mol Pathol 1995;62:99–108

    Article  PubMed  CAS  Google Scholar 

  176. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708–713

    Article  PubMed  CAS  Google Scholar 

  177. Aronow WS. The older man’s heart and heart disease. Med Clin North Am 1999;83:1291–1303

    Article  PubMed  CAS  Google Scholar 

  178. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci 2002;57:M45–M46

    PubMed  Google Scholar 

  179. Woodworth S, Nayak D, Aronow WS, Pucillo AL, Koneru S. Comparison of acute coronary syndromes in men versus women > or = 70 years of age. Am J Cardiol 2002;90:1145–1147

    Article  PubMed  Google Scholar 

  180. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835–842

    Article  PubMed  CAS  Google Scholar 

  181. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O’neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1–121

    Google Scholar 

  182. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970–1062

    Google Scholar 

  183. Woodworth S, Nayak D, Aronow WS, Pucillo AL, Koneru S. Cardiovascular medications taken by patients aged >or=70 years hospitalized for acute coronary syndromes before hospitalization and at hospital discharge. Prev Cardiol 2002;5:173–176

    Article  PubMed  Google Scholar 

  184. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477–1488

    Article  PubMed  CAS  Google Scholar 

  185. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Makijarvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135–142

    Article  PubMed  CAS  Google Scholar 

  186. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, Sharma D, Chew P, Braunwald E. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005;149:217–226

    Article  PubMed  CAS  Google Scholar 

  187. Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV Jr, Ohman EM, Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol 2007;49:1790–1797

    Article  PubMed  Google Scholar 

  188. Chen H, Liu J, Yang M. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev 2006;4:CD004471

    PubMed  Google Scholar 

  189. Heart Failure Society Of America. Myocarditis: Current treatment. J Card Fail 2006;12:e120–e122

    Google Scholar 

  190. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG, Schoen FJ. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3–14

    PubMed  CAS  Google Scholar 

  191. Dec GW Jr, Waldman H, Southern J, Fallon JT, Hutter AM Jr, Palacios I. Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol 1992;20:85–89

    Google Scholar 

  192. Dec GW Jr, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985;312:885–890

    Article  PubMed  Google Scholar 

  193. Kyto V, Saraste A, Voipio-Pulkki LM, Saukko P. Incidence of fatal myocarditis: a population-based study in Finland. Am J Epidemiol 2007;165:570–574

    Article  PubMed  Google Scholar 

  194. Elliott WJ. Systemic hypertension. Curr Probl Cardiol 2007;32:201–259

    Article  PubMed  Google Scholar 

  195. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–223

    PubMed  Google Scholar 

  196. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913

    Article  PubMed  Google Scholar 

  197. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287: 1003–1010

    Article  PubMed  Google Scholar 

  198. Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, Levy D. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 1999;34:381–385

    PubMed  CAS  Google Scholar 

  199. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913

    Article  PubMed  Google Scholar 

  200. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–252

    PubMed  CAS  Google Scholar 

  201. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913

    Article  PubMed  Google Scholar 

  202. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479–486

    Article  PubMed  CAS  Google Scholar 

  203. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003;290:199–206

    Article  PubMed  Google Scholar 

  204. Elliott WJ. Management of hypertension in the very elderly patient. Hypertension 2004;44:800–804

    Article  PubMed  CAS  Google Scholar 

  205. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999;353:793–796

    Article  PubMed  CAS  Google Scholar 

  206. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255–3264

    Article  Google Scholar 

  207. Perry HM Jr, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000;284:465–471

    Article  PubMed  Google Scholar 

  208. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212–216

    Article  PubMed  CAS  Google Scholar 

  209. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757–764

    Article  PubMed  CAS  Google Scholar 

  210. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16:1823–1829

    Article  PubMed  CAS  Google Scholar 

  211. Staessen JA, Gasowski J, Wang JG, Thijs L, Den HE, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865–872

    Article  PubMed  CAS  Google Scholar 

  212. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de FU, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491–1498

    Google Scholar 

  213. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007

    Article  Google Scholar 

  214. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999;353:793–796

    Article  PubMed  CAS  Google Scholar 

  215. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994;272:1932–1938

    Article  PubMed  CAS  Google Scholar 

  216. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001;18:151–164

    Article  PubMed  CAS  Google Scholar 

  217. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055–1076

    Article  PubMed  CAS  Google Scholar 

  218. Snieder H, Harshfield GA, Treiber FA. Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension 2003;41:1196–1201

    Article  PubMed  CAS  Google Scholar 

  219. Snieder H, Treiber FA. The Georgia Cardiovascular Twin Study. Twin Res 2002;5:497–498

    Article  PubMed  Google Scholar 

  220. Imumorin IG, Dong Y, Zhu H, Poole JC, Harshfield GA, Treiber FA, Snieder H. A gene-environment interaction model of stress-induced hypertension. Cardiovasc Toxicol 2005;5:109–132

    Article  PubMed  CAS  Google Scholar 

  221. Truswell AS, Kennelly BM, Hansen JD, Lee RB. Blood pressures of Kung bushmen in Northern Botswana. Am Heart J 1972;84:5–12

    Article  PubMed  CAS  Google Scholar 

  222. Poulter NR, Khaw KT, Mugambi M, Peart WS, Rose G, Sever P. Blood pressure patterns in relation to age, weight and urinary electrolytes in three Kenyan communities. Trans R Soc Trop Med Hyg 1985;79:389–392

    Article  PubMed  CAS  Google Scholar 

  223. Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I, Salvetti A. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997;29:736–743

    PubMed  CAS  Google Scholar 

  224. Hamet P, Thorin-Trescases N, Moreau P, Dumas P, Tea BS, deBlois D, Kren V, Pravenec M, Kunes J, Sun Y, Tremblay J. Workshop: excess growth and apoptosis: is hypertension a case of accelerated aging of cardiovascular cells? Hypertension 2001;37:760–766

    Google Scholar 

  225. Liu JJ, Peng L, Bradley CJ, Zulli A, Shen J, Buxton BF. Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts. Cardiovasc Res 2000;45:729–735

    Article  PubMed  CAS  Google Scholar 

  226. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005;23:1831–1837

    Article  PubMed  CAS  Google Scholar 

  227. Rodriguez-Iturbe B, Sepassi L, Quiroz Y, Ni Z, Wallace DC, Vaziri ND. Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence. J Appl Physiol 2007;102:255–260

    Article  PubMed  CAS  Google Scholar 

  228. Rao DC, Province MA, Leppert MF, Oberman A, Heiss G, Ellison RC, Arnett DK, Eckfeldt JH, Schwander K, Mockrin SC, Hunt SC. HyperGEN Network. A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network. Am J Hypertens 2003;16:148–150

    Google Scholar 

  229. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo AP, Hata A, Corvol P, Lalouel JM. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 1997;60:1448–1460

    Article  PubMed  CAS  Google Scholar 

  230. Kato N, Sugiyama T, Morita H, Kurihara H, Yamori Y, Yazaki Y. Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and meta-analysis on six reported studies. J Hypertens 1999;17:757–763

    Article  PubMed  CAS  Google Scholar 

  231. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99:1786–1797

    PubMed  CAS  Google Scholar 

  232. Sethi AA, Nordestgaard BG, Gronholdt ML, Steffensen R, Jensen G, Tybjaerg-Hansen A. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 2003;41:1202–1211

    Article  PubMed  CAS  Google Scholar 

  233. Zhu X, Chang YP, Yan D, Weder A, Cooper R, Luke A, Kan D, Chakravarti A. Associations between hypertension and genes in the renin-angiotensin system. Hypertension 2003;41:1027–1034

    Article  PubMed  CAS  Google Scholar 

  234. Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, Ogata J, Ogihara T. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation 2000;101:2060–2065

    PubMed  CAS  Google Scholar 

  235. Turner ST, Boerwinkle E, Sing CF. Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension 1999;34:773–778

    PubMed  CAS  Google Scholar 

  236. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, Turner ST, Boerwinkle E. Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000;101:2877–2882

    PubMed  CAS  Google Scholar 

  237. Herrmann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, Arveiler D, Luc G, Morrison C, Hoehe MR, Paul M, Cambien F. Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens 2002;20:229–235

    Article  PubMed  CAS  Google Scholar 

  238. Krushkal J, Xiong M, Ferrell R, Sing CF, Turner ST, Boerwinkle E. Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation. Hum Mol Genet 1998;7:1379–1383

    Article  PubMed  CAS  Google Scholar 

  239. Thiel BA, Chakravarti A, Cooper RS, Luke A, Lewis S, Lynn A, Tiwari H, Schork NJ, Weder AB. A genome-wide linkage analysis investigating the determinants of blood pressure in whites and African Americans. Am J Hypertens 2003;16:151–153

    Article  PubMed  Google Scholar 

  240. Province MA, Kardia SL, Ranade K, Rao DC, Thiel BA, Cooper RS, Risch N, Turner ST, Cox DR, Hunt SC, Weder AB, Boerwinkle E. National Heart, Lung and Blood Institute Family Blood Pressure Program. A meta-analysis of genome-wide linkage scans for hypertension: the National Heart, Lung and Blood Institute Family Blood Pressure Program. Am J Hypertens 2003;16:144–147

    Article  PubMed  Google Scholar 

  241. Koivukoski L, Fisher SA, Kanninen T, Lewis CM, von Wowern F, Hunt S, Kardia SL, Levy D, Perola M, Rankinen T, Rao DC, Rice T, Thiel BA, Melander O. Meta-analysis of genome-wide scans for hypertension and blood pressure in Caucasians shows evidence of susceptibility regions on chromosomes 2 and 3. Hum Mol Genet 2004;13:2325–2332

    Article  PubMed  CAS  Google Scholar 

  242. Mein CA, Caulfield MJ, Dobson RJ, Munroe PB. Genetics of essential hypertension. Hum Mol Genet 2004;13:R169–R175

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Molecular Cardiology and Neuromuscular Institute, Highland Park, New Jersey

    José Marín-García M.D. (Director)

  2. The Molecular Cardiology and Neuromuscular Institute, Highland Park, New Jersey

    Michael J. Goldenthal (Senior Research Scientist)

  3. University of Toronto, St. Michael Hospital, Toronto, Canada

    Gordon W. Moe (Associate Professor)

Authors
  1. José Marín-García M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Goldenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gordon W. Moe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Marín-García, J., Goldenthal, M.J., Moe, G.W. (2008). Atherosclerosis, Hypertension and Aging. In: Aging and the Heart. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-74072-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-74072-0_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-74071-3

  • Online ISBN: 978-0-387-74072-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation